Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research
详细信息 查看全文
- 作者：Mark E. Polhemus ; Alan J. Magill ; James F. Cummings ; Kent E. Kester ; Chris F. Ockenhouse ; David E. Lanar ; Sheetij Dutta ; Arnoldo Barbosa ; Lorraine Soisson ; Carter L. Diggs ; et al.
- 关键词：Apical membrane antigen ; Processing inhibition assay ; FMP2.1 ; AS02A ; Malaria ; Vaccine ; Falciparum ; Recombinant protein ; Growth inhibition assay
- 刊名：Vaccine
- 出版年：2007
- 出版时间：22 May 2007
- 年：2007
- 卷：25
- 期：21
- 页码：4203-4212
- 全文大小：646 K
文摘
We report the first safety and immunogenicity trial of the Plasmodium falciparum vaccine candidate FMP2.1/AS02A, a recombinant E. coli-expressed protein based upon the apical membrane antigen-1 (AMA-1) of the 3D7 clone formulated with the AS02A adjuvant. We conducted an open-label, staggered-start, dose-escalating Phase I trial in 23 malaria-naïve volunteers who received 8, 20 or 40 μg of FMP2.1 in a fixed volume of 0.5 mL of AS02A on a 0, 1, and 2 month schedule. Nineteen of 23 volunteers received all three scheduled immunizations. The most frequent solicited local and systemic adverse events associated with immunization were injection site pain (68 % ) and headache (29 % ). There were no significant laboratory abnormalities or vaccine-related serious adverse events. All volunteers seroconverted after second immunization as determined by ELISA. Immune sera recognized sporozoites and merozoites by immunofluorescence assay (IFA), and exhibited both growth inhibition and processing inhibition activity against homologous (3D7) asexual stage parasites. Post-immunization, peripheral blood mononuculear cells exhibited FMP2.1-specific lymphoproliferation and IFN-γ and IL-5 ELISPOT assay responses. This is the first PfAMA-1-based vaccine shown to elicit both potent humoral and cellular immunity in humans. Encouraged by the potential of FMP1/AS02A to target host immunity against PfAMA-1 that is known to be expressed by sporozoite, hepatic and erythrocytic stages, we have initiated field trials of FMP2.1/AS02A in an endemic population in the Republic of Mali.